Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial
- 16 February 2018
- journal article
- research article
- Published by Springer Nature in Veterinary Research Communications
- Vol. 42 (2) , 121-130
Abstract
The use of natural products is a promising approach for treating visceral leishmaniosis. (-)-α-Bisabolol is a sesquiterpene that have been proved active in vivo on Leishmania infantum-infected mice without showing toxicity. A single-centre, parallel-group, randomized, exploratory study was designed to assess its efficacy in a canine leishmaniosis model involving naturally infected dogs. In this clinical trial, 12 dogs were allocated into two groups and were treated with either meglumine antimoniate (100 mg/kg) through subcutaneous route or (-)-α-bisabolol (30 mg/kg) through oral route for two treatment series of 30 days, separated by a 30-day interval. A 4-month follow-up period was established as well. Parasite loads in bone marrow, lymph node and blood were estimated through quantitative PCR. Antibody titres were determined through immunofluorescence antibody test and cytokine expression values were estimated through real-time reverse transcription-PCR. Treatment safety was assessed through the evaluation of weight, gastrointestinal alterations and hematological and biochemical parameters in blood. Analyses were performed before and after treatment, and after a 4-months follow-up period. Treatment with the sesquiterpene was effective at decreasing parasite loads and increasing gamma-interferon expression level. Dogs treated with (-)-α-bisabolol did not show any toxicity sign. These results were better than those obtained using the reference drug, meglumine antimoniate. The natural compound seemed to induce a Th1 immune response that led to parasitological and clinical improvement without showing any safety issue, suggesting a high potential for the treatment of canine and human visceral leishmaniosis.Keywords
Funding Information
- CEI-Biotic (2013/1/4)
- Universidad de Granada (PR/12/011)
This publication has 36 references indexed in Scilit:
- Therapeutic Options for Visceral LeishmaniasisDrugs, 2013
- In VitroAntileishmanial Activity of Essential Oil ofVanillosmopsis arborea(Asteraceae) BakerEvidence-Based Complementary and Alternative Medicine, 2013
- Epidemiological implications of the use of various methods for the diagnosis of canine leishmaniasis in dogs with different characteristics and in differing prevalence scenariosParasitology Research, 2012
- Frequency of Drug Resistance Gene Amplification in ClinicalLeishmaniaStrainsInternational Journal of Microbiology, 2010
- Canine Leishmaniasis in Southeastern SpainEmerging Infectious Diseases, 2009
- Interferon-gamma (INF-γ), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinolCytokine, 2008
- Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymesLife Sciences, 2006
- Treatment of canine Old World visceral leishmaniasis: a systematic reviewVeterinary Dermatology, 2005
- Immunoglobulin G and E responses in various stages of canine leishmaniosisVeterinary Immunology and Immunopathology, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001